TheraRadar
← Back
Data updated: Nov 8, 2026

KANCHAN HLTHCARE

Specialty
Pharmaceuticals

KANCHAN HLTHCARE is a specialty pharmaceutical company with 1 FDA-approved products.

1967
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

KANCHAN HLTHCARE's Key Drugs

KANCHAN HLTHCARE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

KANCHAN HLTHCARE's Recent FDA Approvals

New NDA/BLA approvals for KANCHAN HLTHCARE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

KANCHAN HLTHCARE's Therapeutic Areas

Disease areas where KANCHAN HLTHCARE has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

KANCHAN HLTHCARE Pipeline Snapshot

Active clinical trials for KANCHAN HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling